Following the initial sequencing of the human genome, it was widely predicted that this knowledge would lead to transformational advances in the identification, prevention, and treatment of disease.1 The terms “Precision Medicine” and “Personalized Medicine” have been used interchangeably over the last two decades to describe almost all applications of genomic information in the development and use of medicinal interventions.2 While there are notable clinical advances that exemplify the highly effective benefit/risk profiles of precision medicine-driven approaches1, 2 the general concept of targeting specific interventions to individual patients continues to be a rich area of translational research. The 19th World Congress of Basic & Clinical Pharmacology (WCP2023) was held in Glasgow Scotland from July 2 to 7, 2023. The British Pharmacological Society and International Union of Basic and Clinical Pharmacologists (IUPHAR) hosted this important international meeting. WCP2023 was attended by more than 2000 delegates from over 80 countries. It is noteworthy that many of the WCP2023 scientific sessions, across a wide range of therapeutic areas, addressed ongoing research relevant to the current state and aspirational goals of precision medicine approaches for improving human health. During WCP2023, the symposium “Experimental Pharmacology in Precision Medicine” presented recent advances and current challenges in the application of precision medicine to diverse areas, including drug metabolism, drug–drug interactions, therapeutic drug dose monitoring and therapeutic interventions for cystic fibrosis (CF). The speakers were Drs. K.E. Thummel, B. Prasad, J. Martin, and D.N. Sheppard and the co-chairs of the symposium were Drs. A. Urbaniak and M.F. Jarvis. Consistent with the goal of highlighting research from early career investigators, the WCP2023 organizers also invited Dr. A. De Nicolò to give an oral presentation based on his submitted abstract on the metabolism of antiretroviral drugs. In the following ...